Patients with NPM1-mutated chemotherapy-related secondary AML show similar survival as patients with de novo NPM1-mutated AML [16], and this is better survival than other patients with therapy-associated AML who have an adverse prognosis [17,18,19]. This evidence concerns the gene NPM1 and acute myeloid leukemia.